Pelthos Therapeutics shares surge 82.73% intraday after launching ZELSUVMI, the first FDA-approved at-home treatment for molluscum contagiosum.

Pelthos Therapeutics Inc. surged 82.73% intraday, with the company launching ZELSUVMI™ (berdazimer) topical gel 10.3%, the first and only FDA-approved at-home treatment for molluscum contagiosum. The company has earned a $5 million milestone payment from Ligand following the commercial launch of ZELSUVMI. The once-daily topical prescription medication is effective, well tolerated, and convenient for at-home or on-the-go application and can be used to treat infections on the body, including sensitive areas.